Emerging data suggest that SBRT may be comparable with surgery for definitive treatment of stage I NSCLC in certain patients. When is one approach preferred and in whom?
Small-cell lung cancer (SCLC) is the most aggressive type of lung cancer. Each year in the U.S., about 30,000 to 35,000 people are diagnosed with it. For most, it has already spread to distant ...
Patients recovering from curative-intent lung cancer surgery with exposure to wildfire disaster have longer lengths of stay in the hospital.
Johnson & Johnson has produced the most convincing data to date that its combination of Rybrevant and Lazcluze could replace ...
Positive preliminary data from the phase 1b/2 trial evaluating Olvi-Vec in small cell lung cancer have been announced.
The latest data from Johnson and Johnson's Rybrevant and Lazcluze lung cancer combo was better than standard of care Tagrisso ...
A new systemic nutrition-inflammation index predicted perioperative non-small cell lung cancer outcomes better than current ...
The first patient has been dosed in the phase 3 TACTI-004 trial evaluating efti with Keytruda and chemotherapy for advanced ...
A multivariate analysis confirmed the independent prognostic significance of both landmark and longitudinal MRD.
SAN ANTONIO, March 26, 2025--bioAffinity Technologies' CyPath Lung test uncovered a hidden second primary lung cancer in a patient who had been treated for lung cancer earlier.
Targeted therapies have significantly improved outcomes for patients with non-small cell lung cancer (NSCLC) with actionable mutations. However, many tumors inevitably develop drug resistance and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback